These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33681331)

  • 1. The Association Between the Use of Oclacitinib and Antibacterial Therapy in Dogs With Allergic Dermatitis: A Retrospective Case-Control Study.
    Rynhoud H; Gibson JS; Meler E; Soares Magalhães RJ
    Front Vet Sci; 2021; 8():631443. PubMed ID: 33681331
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study.
    Rynhoud H; Croton C; Henry G; Meler E; Gibson JS; Soares Magalhaes RJ
    BMC Vet Res; 2022 Apr; 18(1):151. PubMed ID: 35477466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminished antimicrobial drug use in dogs with allergic dermatitis treated with oclacitinib.
    Mwacalimba K; Hillier A; Rosenbaum M; Brennan C; Amodie D
    Front Vet Sci; 2023; 10():1207582. PubMed ID: 37745208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.
    Cosgrove SB; Wren JA; Cleaver DM; Martin DD; Walsh KF; Harfst JA; Follis SL; King VL; Boucher JF; Stegemann MR
    Vet Dermatol; 2013 Oct; 24(5):479-e114. PubMed ID: 23829933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics.
    Gonzales AJ; Fleck TJ; Humphrey WR; Galvan BA; Aleo MM; Mahabir SP; Tena JK; Greenwood KG; McCall RB
    Vet Dermatol; 2016 Feb; 27(1):34-e10. PubMed ID: 26666963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.
    Gadeyne C; Little P; King VL; Edwards N; Davis K; Stegemann MR
    Vet Dermatol; 2014 Dec; 25(6):512-8, e86. PubMed ID: 25109820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis.
    Gonzales AJ; Aleo M; Mahabir S; Messamore J; Stegemann M
    J Vet Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38926932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
    Simpson AC; Schissler JR; Rosychuk RAW; Moore AR
    Vet Dermatol; 2017 Oct; 28(5):485-e113. PubMed ID: 28513001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
    Cosgrove SB; Cleaver DM; King VL; Gilmer AR; Daniels AE; Wren JA; Stegemann MR
    Vet Dermatol; 2015 Jun; 26(3):171-9, e35. PubMed ID: 25688708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL-31-induced pruritus.
    Fleck T; Norris L; King V; Lesman S; Gonzales AJ
    J Vet Pharmacol Ther; 2022 Jul; 45(4):380-384. PubMed ID: 35586953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib.
    Lancellotti BA; Angus JC; Edginton HD; Rosenkrantz WS
    J Am Vet Med Assoc; 2020 Sep; 257(5):507-516. PubMed ID: 32808904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
    Little PR; King VL; Davis KR; Cosgrove SB; Stegemann MR
    Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of an Intradermal Canine IL-31-Induced Pruritus Model to Evaluate Therapeutic Candidates in Atopic Dermatitis.
    Pearson J; Leon R; Starr H; Kim SJ; Fogle JE; Banovic F
    Vet Sci; 2023 May; 10(5):. PubMed ID: 37235412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib.
    Fukuyama T; Ganchingco JR; Bäumer W
    Eur J Pharmacol; 2017 Jan; 794():20-26. PubMed ID: 27847179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs.
    Marsella R; Ahrens K
    Vet Dermatol; 2018 Oct; 29(5):439-e146. PubMed ID: 29926994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot evaluation of Enterococcus faecium SF68 as adjunctive therapy for oclacitinib-responsive adult atopic dermatitis in dogs.
    Yamazaki C; Rosenkrantz W; Griffin C
    J Small Anim Pract; 2019 Aug; 60(8):499-506. PubMed ID: 31257599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats.
    Ortalda C; Noli C; Colombo S; Borio S
    Vet Dermatol; 2015 Aug; 26(4):235-e52. PubMed ID: 25940959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a retrospective case series.
    Colombo S; Cornegliani L; Vercelli A; Fondati A
    Vet Dermatol; 2021 Aug; 32(4):363-e100. PubMed ID: 34250688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of topical oclacitinib and nail trimming as a treatment for murine ulcerative dermatitis in laboratory mice.
    Davison SE; Emmer KM; Ugiliweneza B; Sherwood LC
    PLoS One; 2022; 17(10):e0276333. PubMed ID: 36256616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs.
    Denti D; Caldin M; Ventura L; De Lucia M
    Vet Dermatol; 2022 Apr; 33(2):149-e42. PubMed ID: 35014745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.